Displaying 261 - 280 of 1535
A.S. Research, LLC (Synovia)
The marketers of a dietary supplement called Synovia agreed to settle FTC charges by halting the deceptive tactics they allegedly used to mislead consumers into thinking Synovia could treat arthritis and alleviate joint pain. In December 2020, the Commission announced it was returning almost $775,000 to consumers who both the deceptively marketed product.
Otto Bock HealthCare North America, Inc., In the Matter of
The FTC issued an administrative complaint challenging the merger of two prosthetics manufacturers that are top sellers of prosthetic knees equipped with microprocessors. According to the FTC’s complaint, Otto Bock’s consummated acquisition of FIH Group Holdings (owner of Freedom Innovations) harmed competition in the U.S. market for microprocessor prosthetic knees by eliminating head-to-head competition between the two companies, removing a significant and disruptive competitor, and entrenching Otto Bock’s position as the dominant supplier. Microprocessor knees, which use microprocessors to adjust the stiffness and positioning of the joint in response to variations in walking rhythm and ground conditions, provide a stable platform for amputees. Compared to other products, microprocessor prosthetic knees reduce the risk of falling, cause less pain, and promote the health and function of the sound limb. In addition to issuing an administrative complaint, the Commission authorized agency staff to seek a temporary restraining order, preliminary injunction, and ancillary relief in federal court, should doing so be necessary to ensure the Freedom Innovations business remains viable and to preserve the Commission ability to order effective relief. On Dec. 1, 2020, the Commission announced approval for the divestiture of the Freedom assets.
Statement of Commissioner Christine S. Wilson, Joined by Commissioner Noah Joshua Phillips, In the Matter of Methodist Le Bonheur Healthcare
FTC Sues to Block Proposed Acquisition of Two Memphis-Area Hospitals
Pfizer Inc. and Mylan N.V.; Analysis of Agreement Containing Consent Orders To Aid Public Comment
PrivacyCon 2021
Stryker and Wright Medical; Analysis of Consent Orders To Aid Public Comment
Sunday Riley Modern Skincare, LLC; In the Matter of
On October 21, 2019, the FTC announced it had halted the deceptive online marketing tactics of cosmetics firm Sunday Riley Modern Skincare, LLC and its CEO. Under the order settling the FTC’s complaint the defendants were banned from misleading consumers by posting fake reviews of the company’s products on a major retailer’s website, at the CEO’s direction, and by failing to disclose that the reviewers were company employees. The FTC announced approval of the final order in November 2020.
Statement of Commissioner Rohit Chopra in the Matter of Stryker and Wright Medical
FTC Requires Medical Device Companies Stryker Corp. and Wright Medical Group N.V. to Divest Assets to Preserve Competition
Statement of Commissioner Christine S. Wilson in the Matter of Pfizer Inc./Mylan N.V.
Dissenting Statement of Commissioner Rohit Chopra Joined by Commissioner Rebecca Kelly Slaughter in the Matter of Pfizer Inc./Mylan N.V.
Statement of Commissioner Rohit Chopra Regarding the Report to Congress on Protecting Older Consumers
FTC Requests Public Comment on Otto Bock HealthCare North America, Inc.’s Application to Approve Divestiture of Assets It Gained through Acquisition of FIH Group Holdings, LLC
FTC Staff Submits Public Comment in Texas Opposing Certificate of Public Advantage Applications
FTC Staff Comment to Texas Health and Human Services Commission Regarding Certificate of Public Advantage Applications
FTC Staff Comment to Attorney General of Texas Concerning Certified Registered Nurse Anesthetists (CRNA) Regulations
FTC Comment to Texas Attorney General Raises Concerns about Likely Competitive Effect of Proposed Regulations Imposing Additional Supervisory Requirements on Texas Certified Nurse Anesthetists
AbbVie Inc. and Allergan plc, In the Matter of
Pharmaceutical companies AbbVie Inc. and Allergan plc have agreed to divest assests to settle Federal Trade Commission charges that AbbVie's proposed $63 billion acquisition of Allergan would violate federal antitrust law. On Sept. 4, 2020, the Commission announced the final consent agreement in this matter.
Displaying 261 - 280 of 1535